U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07662473) titled 'The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression' on June 16.
Brief Summary: This is a single arm, multicenter and prospective study to evaluate the efficacy and safety of T-DXd for the treatment in locally advanced, unresectable, or metastatic participants with selected HER2 positive (IHC 3+) NSCLC which are not eligible for curative therapy
Study Start Date: July 29
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DRUG: Experimental Group
All participants enrolled in the study will receive the study intervention (T-DXd) 5.4 mg/kg as an IV infusion Q3W, on D...